Mutation of the ERβ phosphotyrosine switch impairs CD8+ T cell function and promotes tumor growth, while the ERβ agonist S-equol boosts TCR activation and enhances anti-PD-1 immunotherapy, suggesting ERβ as a potential target for improving cancer immunotherapy (42). Here, CD8A is linked to neoplasm.